Insider Selling: Privia Health Group (NASDAQ:PRVA) CEO Sells $354,248.08 in Stock

Posted by Amy Steele on May 16th, 2026

Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CEO Parth Mehrotra sold 15,647 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $22.64, for a total transaction of $354,248.08. Following the transaction, the chief executive officer directly owned 434,357 shares of the company’s stock, valued at $9,833,842.48. The trade was a 3.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Parth Mehrotra also recently made the following trade(s):

On Monday, May 11th, Parth Mehrotra sold 105,439 shares of Privia Health Group stock. The shares were sold at an average price of $22.55, for a total transaction of $2,377,649.45.
On Monday, March 16th, Parth Mehrotra sold 26,509 shares of Privia Health Group stock. The shares were sold at an average price of $22.11, for a total transaction of $586,113.99.
On Friday, March 13th, Parth Mehrotra sold 27,229 shares of Privia Health Group stock. The shares were sold at an average price of $21.52, for a total transaction of $585,968.08.
On Thursday, March 12th, Parth Mehrotra sold 26,763 shares of Privia Health Group stock. The shares were sold at an average price of $21.90, for a total transaction of $586,109.70.
On Tuesday, March 10th, Parth Mehrotra sold 21,097 shares of Privia Health Group stock. The shares were sold at an average price of $22.71, for a total transaction of $479,112.87.
On Monday, March 9th, Parth Mehrotra sold 41,999 shares of Privia Health Group stock. The shares were sold at an average price of $22.86, for a total transaction of $960,097.14.
On Friday, March 6th, Parth Mehrotra sold 21,440 shares of Privia Health Group stock. The shares were sold at an average price of $23.15, for a total transaction of $496,336.00.

Privia Health Group Stock Down 1.2%

PRVA opened at $22.95 on Friday. The firm has a 50 day moving average price of $22.62 and a 200-day moving average price of $23.23. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of 143.45, a PEG ratio of 1.71 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a net margin of 0.97% and a return on equity of 2.81%. The business had revenue of $603.85 million during the quarter, compared to analysts’ expectations of $560.99 million. During the same period in the prior year, the company earned $0.22 earnings per share. The firm’s revenue was up 25.8% on a year-over-year basis. As a group, analysts expect that Privia Health Group, Inc. will post 0.35 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on PRVA shares. Canaccord Genuity Group reduced their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a report on Friday, May 8th. Barclays upped their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Wednesday, March 25th. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Truist Financial upped their target price on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, Evercore set a $26.00 target price on shares of Privia Health Group in a report on Wednesday, April 8th. Eleven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.23.

Check Out Our Latest Stock Analysis on PRVA

Hedge Funds Weigh In On Privia Health Group

A number of hedge funds have recently modified their holdings of PRVA. Van Berkom & Associates Inc. boosted its position in shares of Privia Health Group by 30.1% in the third quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company’s stock worth $93,987,000 after purchasing an additional 873,344 shares during the period. Vanguard Group Inc. boosted its position in shares of Privia Health Group by 5.3% in the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after purchasing an additional 607,447 shares during the period. ArrowMark Colorado Holdings LLC boosted its position in shares of Privia Health Group by 139.4% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company’s stock worth $19,946,000 after purchasing an additional 489,866 shares during the period. Algert Global LLC boosted its position in shares of Privia Health Group by 277.4% in the third quarter. Algert Global LLC now owns 484,304 shares of the company’s stock worth $12,059,000 after purchasing an additional 355,966 shares during the period. Finally, Freestone Grove Partners LP boosted its position in shares of Privia Health Group by 40.6% in the fourth quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company’s stock worth $28,768,000 after purchasing an additional 350,194 shares during the period. 94.48% of the stock is currently owned by institutional investors.

About Privia Health Group

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.